U.S. markets closed
  • S&P Futures

    4,565.25
    0.00 (0.00%)
     
  • Dow Futures

    35,645.00
    +1.00 (+0.00%)
     
  • Nasdaq Futures

    15,534.00
    -11.00 (-0.07%)
     
  • Russell 2000 Futures

    2,289.80
    -4.10 (-0.18%)
     
  • Crude Oil

    84.23
    -0.42 (-0.50%)
     
  • Gold

    1,789.00
    -4.40 (-0.25%)
     
  • Silver

    24.08
    -0.01 (-0.05%)
     
  • EUR/USD

    1.1605
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6190
    -0.0160 (-0.98%)
     
  • Vix

    15.98
    +0.74 (+4.86%)
     
  • GBP/USD

    1.3775
    +0.0012 (+0.08%)
     
  • USD/JPY

    114.0380
    -0.0910 (-0.08%)
     
  • BTC-USD

    60,586.38
    -2,114.20 (-3.37%)
     
  • CMC Crypto 200

    1,471.55
    -33.60 (-2.23%)
     
  • FTSE 100

    7,277.62
    +54.80 (+0.76%)
     
  • Nikkei 225

    28,946.61
    -159.40 (-0.55%)
     

Bellerophon to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that Fabian Tenenbaum, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Virtual BioConnect 2021 Conference, being held January 11-14, 2021.

The presentation will be available on-demand beginning on Monday, January 11, 2021, in the Investors section on the Company’s website at www.bellerophon.com.

About Bellerophon
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary and infectious diseases. The Company is currently developing multiple product candidates under its INOpulse® program, a proprietary pulsatile nitric oxide delivery system. For more information, please visit www.bellerophon.com.

Contacts

At W2O Group:

At LifeSci Advisors:

Julie Normart

Brian Ritchie

(559) 974-3245

(212) 915-2578

jnormart@w2ogroup.com

britchie@lifesciadvisors.com